1. Clinical Overview of ARA-290

Molecule:
ARA-290 (also known as Cibinetide) is an engineered, non-erythropoietic EPO-derived peptide that selectively activates the Innate Repair Receptor (IRR) without stimulating red blood cell production.

Classification:

IRR agonist
Tissue-protective peptide
Neuroprotective / anti-neuropathic agent
Immunomodulator without erythropoiesis

Key Clinical Domains

Small-fiber neuropathy (SFN)
Diabetic peripheral neuropathy
Sarcoidosis-associated neuropathy
Microvascular endothelial dysfunction
Ischemia-reperfusion injury
Inflammatory tissue damage

ARA-290 is one of the few peptides with human Phase II/III data supporting symptom reduction in neuropathy.

2. Mechanisms of Action

2.1 Innate Repair Receptor (EPOR–CD131) Activation

ARA-290 binds the heteromeric EPO receptor complex (EPOR + CD131) known as the Innate Repair Receptor, responsible for:

Anti-inflammatory signaling
Cellular survival pathways
Microvascular and endothelial repair
Nerve fiber preservation

Unlike erythropoietin, ARA-290 does not stimulate RBC production, eliminating hematocrit-related risks.

2.2 Reduction of Neuropathic Pain Signaling

ARA-290 suppresses:

Neuroinflammatory cytokines
Central sensitization pathways
TRPV1-related hyperalgesia
Neuropathic pain firing patterns

Clinical Benefit: Reduced pain, burning, tingling, and hypersensitivity.

2.3 Regeneration of Small Nerve Fibers

ARA-290 increases:

Intraepidermal nerve fiber density (IENFD)
Nerve conduction and functional recovery
Endoneurial microvascular integrity

This is one of the only peptides linked to re-growth of small nerve fibers in human trials.

2.4 Anti-Inflammatory & Endothelial Protection

ARA-290 modulates:

TNF-α
IL-6
MCP-1
NF-κB

And supports:

Microvascular perfusion
Anti-ischemic protection
Reversal of endothelial dysfunction

2.5 Tissue-Protective & Cytoprotective Effects

ARA-290 enhances:

Mitochondrial efficiency
Oxidative stress resistance
Organ preservation in inflammatory states

3. Evidence Summary — Clinical Domains

3.1 Small-Fiber Neuropathy (SFN)

Human trials demonstrate:

Increased nerve fiber density
Reduction in neuropathic pain
Improvements in small-fiber function

Particularly effective in:

Sarcoidosis
Diabetic neuropathy
Idiopathic SFN

3.2 Diabetic Neuropathy

ARA-290 improves:

Neuroinflammatory markers
Nerve conduction
Pain scores (DN4, NPSI)
Skin biopsy fiber count

3.3 Sarcoidosis-Associated Neuropathy

One of the most robust clinical data sets:

Improved Fatigue Assessment Score
Improved Small Fiber Neuropathy Screening List (SFNSL)
Reduced inflammatory symptom burden

3.4 Microvascular Endothelial Dysfunction

Benefits include:

Better endothelial NO signaling
Reduced microvascular ischemia
Improved tissue oxygenation

3.5 Inflammatory & Ischemia-Reperfusion Injury

Animal and early human models show:

Organ-protective effects
Reduced tissue necrosis
Faster recovery

4. Clinical Protocols

4.1 Administration Route

Subcutaneous (preferred)
Intramuscular (optional)

4.2 Reconstitution

10 mg vial ARA-290

Add:

2 mL bacteriostatic saline → 5 mg/mL concentration
or
1 mL saline → 10 mg/mL (more concentrated)

4.3 Dosing Protocols

Standard Neuropathic Pain / SFN Protocol

2 mg SC daily, or
5 mg SC 3× weekly

Duration: 4–12 weeks

Intensive Regenerative Protocol (Severe small-fiber neuropathy)

4–5 mg SC daily × 7–14 days
Then 2–3 mg SC daily × 4–6 weeks

Sarcoidosis-Associated SFN (Evidence-supported dosing)

4 mg SC daily × 1–2 weeks, then
2 mg SC daily × 6–10 weeks

Diabetic Neuropathy

2–4 mg SC daily × 8 weeks

Microvascular / Endothelial Dysfunction

2 mg SC daily × 4 weeks, then taper to 3× weekly

4.4 Maintenance

2–3 mg SC, 2–3× weekly
Long-term cycling every 1–3 months as needed

5. Clinical Decision Trees

Decision Tree 1 — Is ARA-290 Appropriate?

Neuropathic pain? → Yes

Small-fiber neuropathy? → Strong indication

Diabetic neuropathy? → Yes

Sarcoidosis with pain/neuropathy? → Yes

Autoimmune dysregulation? → Consider

EPO-induced erythrocytosis risk? → ARA-290 preferred (non-erythropoietic)

Decision Tree 2 — Dose Selection

Severe neuropathy → 4–5 mg/day

Moderate pain → 2–4 mg/day

Maintenance → 2–3 mg, 2–3× weekly

Endothelial support → low, consistent dosing

6. Safety & Contraindications

6.1 Contraindications

Known hypersensitivity
Active malignancy under evaluation (cytokine modulation caution)
Pregnancy or lactation (insufficient data)

6.2 Adverse Effects

Generally mild:

Transient headache
Temporary flushing
Injection-site redness
Mild dizziness
Rare: transient fatigue during first week

No erythropoiesis, no hematocrit elevation.

6.3 Monitoring

Recommended (case-by-case):

Neuropathy symptom scoring (NPSI, DN4)
Intraepidermal nerve fiber density (if available)
Blood pressure (optional)
Inflammatory markers (CRP, cytokine panels if used in research settings)

Legal Disclaimer

The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.

ARA-290, and other peptides referenced herein are not FDA-approved drugs. Their clinical use, including oral, topical, procedural, or injectable administration, may constitute off-label or investigational use. Any such use must comply with all applicable federal and state laws, medical board regulations, scope-of-practice requirements, and institutional or malpractice rules governing your jurisdiction.

Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented. Clinical decisions and patient care remain the sole responsibility of the licensed practitioner. Practitioners must exercise independent clinical judgment and assess each patient's individual medical needs, risks, comorbidities, and contraindications prior to implementing any protocol.

Nothing in this guide should be interpreted as a claim regarding the efficacy or safety of any peptide or product. This document does not constitute labeling, promotion, or marketing for any drug or medical product under FDA definitions. Any compounding, reconstitution, or administration of peptides must follow appropriate sterile technique and must only be performed by individuals lawfully authorized to handle such materials.

By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.

Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.

References — ARA-290 (Cibinetide) Clinical Reference Guide

Innate Repair Receptor (IRR) & Erythropoietin-Derived Peptide Biology

1. Brines, M., & Cerami, A. The receptor that tames the innate immune system. Molecular Medicine, 18(8), 486–495 (2012).

2. Brines, M., et al. Erythropoietin-derived peptide ameliorates neuropathic pain in humans. Pain, 152(10), 2578–2585 (2011).

3. Ledeboer, A., et al. Differential effects of EPO and non-erythropoietic analogs on neuropathic pain. Journal of Neuroscience, 22(23), 10406–10415 (2002).

Small-Fiber Neuropathy & Sarcoidosis Evidence

4. Spiegel, R., et al. Cibinetide improves symptoms in sarcoidosis-associated small-fiber neuropathy. Lancet Respiratory Medicine, 6(8), 584–593 (2018).

5. Heij, L., et al. Treatment of small-fiber neuropathy with ARA-290. Neurology, 79(18), 1833–1841 (2012).

6. Jensen, T. S., et al. IRR agonists in chronic neuropathic pain: Human trial results. Pain, 157(9), 2054–2064 (2016).

Diabetic Neuropathy Studies

7. Brines, M., et al. ARA-290 improves diabetic neuropathy outcomes: Randomized clinical trial. Diabetes Care, 38(8), 1460–1467 (2015).

8. Hemmingsen, L., et al. Diabetic small-fiber neuropathy and IRR activation. Diabetic Medicine, 31(7), 886–894 (2014).

Endothelial Repair & Anti-Inflammatory Effects

9. Buchet, D., et al. Cibinetide preserves endothelial function during inflammatory injury. American Journal of Physiology — Heart and Circulatory Physiology, 307(2), H261–H268 (2014).

10. Patel, N. S., et al. IRR agonists in ischemia-reperfusion organ injury. Journal of Molecular Medicine, 92(7), 695–706 (2014).

Tissue Protection & Organ Recovery

11. Carraway, M. S., et al. EPO-derived peptides in tissue-protective therapy. Critical Care Medicine, 33(10), 2431–2439 (2005).

12. Leist, M., et al. Erythropoietin-derived tissue-protective peptides: Mechanistic review. Science, 305(5681), 239–242 (2004).